My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

12.81 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
New Study Shows Ibogaine Can Be Made Without Using Plant Matter
Via Investor Brand Network
Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)
From Mind Medicine Inc.
Via Business Wire
MindMed to Participate in September Investor Conferences
From Mind Medicine Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
MindMed Reports Q2 2025 Financial Results and Business Updates
From Mind Medicine Inc.
Via Business Wire
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine (MindMed) Inc.
Via Business Wire
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
From FN Media Group LLC
Via GlobeNewswire
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
MindMed to Participate in June Investor Conferences
From Mind Medicine Inc.
Via Business Wire
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer
From Mind Medicine Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates
From Mind Medicine Inc.
Via Business Wire
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
Study Finds That the Mental Wellbeing Effects of Psilocybin Vary by Race
Via Investor Brand Network
MindMed Appoints Matt Wiley as Chief Commercial Officer
From Mind Medicine Inc.
Via Business Wire
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
From Mind Medicine Inc.
Via Business Wire
MindMed to Present at Leerink’s Global Healthcare Conference 2025
From Mind Medicine Inc.
Via Business Wire
Groups of Military Veterans Urge Congress to Expedite Research on Psychedelics
Via Investor Brand Network
Topics Cannabis
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
From Mind Medicine Inc.
Via Business Wire
MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Mind Medicine Inc.
Via Business Wire
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
From Mind Medicine (MindMed) Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.